LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2. - Dataset (ID:20246)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Y39983 | 10 | uM | LJP6 | 3 | P01 | 72 | hr | 2543 | 1883 | 5557 | 0.3388 | -0.2341 |
| SK-BR-3 | Nintedanib | 0.04 | uM | LJP6 | 1 | H06 | 72 | hr | 2543 | 5667 | 5258 | 1.0776 | 1.1479 |
| SK-BR-3 | Nintedanib | 0.04 | uM | LJP6 | 2 | H06 | 72 | hr | 2543 | 5617 | 5438 | 1.0329 | 1.0599 |
| SK-BR-3 | Nintedanib | 0.04 | uM | LJP6 | 3 | H06 | 72 | hr | 2543 | 6053 | 5557 | 1.0892 | 1.1574 |
| SK-BR-3 | Nintedanib | 0.12 | uM | LJP6 | 1 | H05 | 72 | hr | 2543 | 5376 | 5258 | 1.0223 | 1.0425 |
| SK-BR-3 | Nintedanib | 0.12 | uM | LJP6 | 2 | H05 | 72 | hr | 2543 | 5316 | 5438 | 0.9775 | 0.9590 |
| SK-BR-3 | Nintedanib | 0.12 | uM | LJP6 | 3 | H05 | 72 | hr | 2543 | 5721 | 5557 | 1.0294 | 1.0521 |
| SK-BR-3 | Nintedanib | 0.37 | uM | LJP6 | 1 | H04 | 72 | hr | 2543 | 5386 | 5258 | 1.0242 | 1.0461 |
| SK-BR-3 | Nintedanib | 0.37 | uM | LJP6 | 2 | H04 | 72 | hr | 2543 | 4910 | 5438 | 0.9029 | 0.8221 |
| SK-BR-3 | Nintedanib | 0.37 | uM | LJP6 | 3 | H04 | 72 | hr | 2543 | 5398 | 5557 | 0.9713 | 0.9491 |
| SK-BR-3 | Nintedanib | 1.11 | uM | LJP6 | 1 | H03 | 72 | hr | 2543 | 5022 | 5258 | 0.9550 | 0.9140 |
| SK-BR-3 | Nintedanib | 1.11 | uM | LJP6 | 2 | H03 | 72 | hr | 2543 | 4963 | 5438 | 0.9126 | 0.8400 |
| SK-BR-3 | Nintedanib | 1.11 | uM | LJP6 | 3 | H03 | 72 | hr | 2543 | 5001 | 5557 | 0.8999 | 0.8214 |
| SK-BR-3 | Nintedanib | 3.33 | uM | LJP6 | 1 | H02 | 72 | hr | 2543 | 4384 | 5258 | 0.8336 | 0.6812 |
| SK-BR-3 | Nintedanib | 3.33 | uM | LJP6 | 2 | H02 | 72 | hr | 2543 | 4516 | 5438 | 0.8304 | 0.6882 |
| SK-BR-3 | Nintedanib | 3.33 | uM | LJP6 | 3 | H02 | 72 | hr | 2543 | 4536 | 5557 | 0.8162 | 0.6704 |
| SK-BR-3 | Nintedanib | 10 | uM | LJP6 | 1 | H01 | 72 | hr | 2543 | 3609 | 5258 | 0.6863 | 0.3964 |
| SK-BR-3 | Nintedanib | 10 | uM | LJP6 | 2 | H01 | 72 | hr | 2543 | 3930 | 5438 | 0.7227 | 0.4872 |
| SK-BR-3 | Nintedanib | 10 | uM | LJP6 | 3 | H01 | 72 | hr | 2543 | 3882 | 5557 | 0.6985 | 0.4550 |
| SK-BR-3 | Foretinib | 0.04 | uM | LJP5 | 1 | H12 | 72 | hr | 2543 | 5936 | 5734 | 1.0351 | 1.0598 |
| SK-BR-3 | Foretinib | 0.04 | uM | LJP5 | 2 | H12 | 72 | hr | 2543 | 5792 | 5761 | 1.0053 | 1.0090 |
| SK-BR-3 | Foretinib | 0.04 | uM | LJP5 | 3 | H12 | 72 | hr | 2543 | 5897 | 5760 | 1.0236 | 1.0400 |
| SK-BR-3 | Foretinib | 0.12 | uM | LJP5 | 1 | H11 | 72 | hr | 2543 | 5385 | 5734 | 0.9391 | 0.8956 |
| SK-BR-3 | Foretinib | 0.12 | uM | LJP5 | 2 | H11 | 72 | hr | 2543 | 5144 | 5761 | 0.8928 | 0.8168 |
| SK-BR-3 | Foretinib | 0.12 | uM | LJP5 | 3 | H11 | 72 | hr | 2543 | 5309 | 5760 | 0.9216 | 0.8662 |